본문 바로가기
KERD
논문KCI 등재

한국인의 임상분리 아스페르길루스 균주에 대한 보리코나졸의 생체외 감수성

In-Vitro Susceptibilities of Voriconazole Against Korean Clinical Aspergillus Isolates

박영규|신명근|박미라|신동현|송정원|정숙인|양동욱|기승정|서순팔|조덕|신종희
대한의진균학회 (The Korean Society for Medical Mycology)|2004.09|대한의진균학회지 (Journal of Mycology and Infection)|제9권 제3호|pp. 166-173

2

조회

0

다운로드

3

인용

0

참고문헌

주제분류미생물학

초록

Abstract

Background: Voriconazole is a potent new triazole antifungal agent expected to be particularly useful for the treatment of invasive aspergillosis. However, in vitro susceptibility of voriconazole for clinical strains of Aspergillus species isolated in Korea has not been fully surveyed. Objective: We determined minimum inhibitory concentrations (MICs) of voriconazole for clinical Aspergillus isolates. Methods: A total of 100 clinical isolates of Aspergillus species (40 A. fumigatus, 24 A. flavus, 17 A. niger, 17 A. terreus and 2 A. nidulans) was tested. In vitro voriconazole susceptibility testing was accomplished utilizing the National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method M38-A. MIC of voriconazole was determined using RPMI medium at 48 h of incubation. Results: Among the 100 isolates of Aspergillus species tested, 98% were inhibited by ≤ 1 μg/mL of voriconazole. The MICs of voriconazole ranged from 0.125 to 2 μg/mL (geometric mean MIC, 0.52 μg/mL). The MIC50 (MIC at which 50% of the isolates tested were inhibited) and MIC90 were 0.5 and 1.0 μg/mL for all Aspergillus species, respectively. The strains showing MIC≥2 μg/mL were 0/40 (0%) in A. fumigatus, 1/24 (4%) in A. flavus, 1/17 (6%) in A. niger, 0/17 (0%) in A. terreus, and 0/2 (0%) in A. nidulans. Conclusion: These data demonstrate promising in-vitro activity of voriconazole against clinical strains of Aspergillus species isolated from Korean patients.

참고문헌 (30)

  1. "침습성 아스페르길루스증", 7, pp.14~21 (2000)
  2. "Aspergillosis", 8, pp.413~437 (1989)
  3. "Therapeutic outcome in invasive aspergillosis", 23, pp.608~615 (1996)
  4. "Invasive aspergillosis", 26, pp.781~805 (1998)
  5. "Invasive aspergillosis.", 79, pp.250~260 (2000)
  6. "Aspergillus, Fusarium, and other opportunistic moniliaceous fungi. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology", pp.1726~1760 (1999)
  7. "Fungal discitis due to Aspergillus terreus in a patient with acute lymphoblastic leukemia", 15, pp.704~707 (2000)
  8. "Aspergillus nidulans infection in a patient with chronic granulomatous disease", 12, pp.244~248 (1997)
  9. "Amphotericin B colloidal dispersion vs.amphotericin B as therapy for invasive aspergillosis", 24, pp.635~642 (1997)
  10. "NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis", 97, pp.135~144 (1994)
  11. "Treatment of invasive aspergillosis", 37(2), pp.20~26 (1994)
  12. "Correlation between in-vitro susceptibility testing to itraconazole and in-vivo coutcome of Aspergllus fumigatus infection", 40, pp.401~414 (1997)
  13. "Voriconazole", 25, pp.1321~1381 (2003)
  14. "Voriconazole:A new triazole antifungal agent", 37, pp.420~432 (2003)
  15. "Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.", pp.1440~1446 (2003)
  16. "Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000.", 46, pp.1032~1037 (2002)
  17. "E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: Comparison with NCCLS broth microdilution method.", 40, pp.2101~2107 (2002)
  18. "Reference method for broth dilution antifungal susceptibility testing of filamentous fungi" (2002)
  19. "Acquired itraconazole resistance in Aspergillus fumigatus", 47, pp.333~340 (2001)
  20. "Itraconazole resistance in Aspergillus fumigatus", 41, pp.1364~1368 (1997)
  21. "In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis", 42, pp.497~502 (1998)
  22. "In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus,with a head- to-head comparison to voriconazole", 37, pp.2343~2345 (1999)
  23. "Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.", 45, pp.1828~1835 (2001)
  24. "In vitro susceptibility testing of Aspergillus spp.: Comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.", 41, pp.1126~1129 (2003)
  25. "In-vitro activity of voriconazole,itraconazole and amphotericin B against filamentous fungi", 42, pp.741~745 (1998)
  26. "Antifungal activity of a new triazole against clinical isolates of Aspergillus spp", 6, pp.101~103 (2000)
  27. "임상검체에서 분리된 Aspergillus Species의 Amphotericin B에 대한 생체외 감수성", 19, pp.33~42 (2001)
  28. "In vitro fungicidal activities of vor- iconazole,itraconazole,and amphotericin B against opportunistic moniliaceous and dematiaceous fungi", 39, pp.954~958 (2001)
  29. "항진균제 감수성 검사와 임상적 응용", 16, pp.291~298 (1998)
  30. "항진균제 감수성 검사와 임상적 응용", 16, pp.291~298 (1998)

관련 논문AI추천

CLSI 액체배지 미량희석법, Etest 및 Minimum Fungicidal Concentration 검사에 의한 국내 혈액에서 분리된 효모균의 시험관 내 Amphotericin B 내성 성적어영, 기승정, 김수현, 김의종, 박지영, 서순팔, 신명근, 신종희, 양동욱대한진단검사의학회 · Annals of Laboratory Medicine2008 · 제28권 제5호Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea김수현, 박연준, 신종희, 이경원, 이위교, 정숙인, 주민영, 최현정대한진단검사의학회 · Annals of Laboratory Medicine2012 · 제32권 제6호임상검체에서 분리된 아스페르길루스 균주의 Echinocandin에 대한 생체 외 감수성조덕, 기승정, 김수현, 박경화, 서순팔, 신명근, 신종희, 양동욱, 이진솔, 정숙인, 최현우대한감염학회 · Infection and Chemotherapy2007 · 제39권 제3호Species Distribution and Susceptibility to Azole Antifungals of Candida Bloodstream Isolates from Eight University Hospitals in Korea어영, 김미나, 김수현, 서순팔, 신명근, 신보문, 신종희, 양동욱, 이경원, 이위교, 이진솔, 이혜수, 장철훈연세대학교의과대학 · Yonsei Medical Journal2007 · 제48권 제5호First Case of Echinocandin-Resistant Candida albicans in Korea강철인, 박민승, 박종은, 송동준, 신종희, 이남용, 허희재, 박실비아대한진단검사의학회 · Annals of Laboratory Medicine2017 · 제37권 제6호In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values김미나, 김수현, 서순팔, 송은송, 신명근, 신종희, 양동욱, 이경원, 이미경, 이위교, 이혜수, 장민중, 장철훈, 장희창대한진단검사의학회 · Annals of Laboratory Medicine2013 · 제33권 제3호

이 간행물의 다른 논문 (4건)

발톱 조갑진균증에서의 Itraconazole 경구 복용과 5% Amorolfine Nail Lacquer 도포의 병합 요법에 의한 치료 효과윤양현, 노병인, 안지영pp. 159-165정상 성인 피부에서 Malassezia 효모균의 분포에 대한 정성적 고찰장수정, 안규중, 최용범, 임선미pp. 174-181감압가열에 의한 급속 건조가 진균의 생존에 미치는 영향김기홍, 박진우, 최종수, 박소현, 신동훈pp. 182-189피부 및 폐 결절을 보인 Coccidioidomycosis 1예김신우, 박동재, 나건연, 이석종, 김도원, 장윤환pp. 190-195
원문 보기